Gavin Xia
Net worth: 301 M $ as of 30/06/2026
Net worth: 301 M $ as of 30/06/2026
Dr. Gavin Xia is a Chief Executive Officer at Alebund Pharmaceuticals (Jiangsu) Ltd., a Chief Executive Officer at Shanghai Alebund Pharmaceutical Technology Co., Ltd. and a Venture Partner at LAV Management Co., Ltd. Dr. Xia was previously employed as a Non-Executive Director by Abbisko Cayman Ltd. and a Non-Executive Director by Abbisko Therapeutics Co., Ltd. He also served on the board at Shanghai Kun Yuan Biotechnology Co. Ltd. and Beijing Jiakesi New Drug Development Co. Ltd. He received his undergraduate degree from Peking University and a doctorate degree from The University of Chicago.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
11.33% | 29/06/2026 | 3,20,69,014 ( 11.33% ) | 188 M $ | 30/06/2026 |
8.54% | 29/06/2026 | 1,94,01,461 ( 8.54% ) | 114 M $ | 30/06/2026 |
| Companies | Position | Start |
|---|---|---|
LAV Management Co., Ltd.
LAV Management Co., Ltd. Investment ManagersFinance LAV invests in companies located in China and the United States. The firm targets companies operating in the fields of biopharmaceuticals, human therapeutics, medical devices and diagnostics. It provides financing for seed, early and later stage capital requirements. | Private Equity Investor | - |
Shanghai Alebund Pharmaceutical Technology Co., Ltd.
Shanghai Alebund Pharmaceutical Technology Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company, focuses on novel therapies discovery and development for kidney diseases | Chief Executive Officer | - |
| Companies | Position | End |
|---|---|---|
| ABBISKO CAYMAN LIMITED | Director/Board Member | 19/06/2023 |
Shanghai Kun Yuan Biotechnology Co. Ltd. | Director/Board Member | 01/02/2021 |
Beijing Jiakesi New Drug Development Co. Ltd.
Beijing Jiakesi New Drug Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Develops and sells drugs | Director/Board Member | - |
Abbisko Therapeutics Co., Ltd.
Abbisko Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology Researches and develops biomedicine and biotechnology | Director/Board Member | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 8 |
|---|---|
Peking University
Peking University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Chicago
The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LAV Management Co., Ltd.
LAV Management Co., Ltd. Investment ManagersFinance LAV invests in companies located in China and the United States. The firm targets companies operating in the fields of biopharmaceuticals, human therapeutics, medical devices and diagnostics. It provides financing for seed, early and later stage capital requirements. | Finance |
Abbisko Therapeutics Co., Ltd.
Abbisko Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology Researches and develops biomedicine and biotechnology | Health Technology |
Beijing Jiakesi New Drug Development Co. Ltd.
Beijing Jiakesi New Drug Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Develops and sells drugs | Health Technology |
Shanghai Alebund Pharmaceutical Technology Co., Ltd.
Shanghai Alebund Pharmaceutical Technology Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company, focuses on novel therapies discovery and development for kidney diseases | Health Technology |
Abbisko Cayman Ltd.
Abbisko Cayman Ltd. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company dedicated to the discovery and development of small molecule oncology therapies | Health Technology |
Shanghai Kun Yuan Biotechnology Co. Ltd. |
Select your edition
All financial news and data tailored to specific country editions